Journal of Hematology & Oncology (Jan 2022)

RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential

  • Jianwei Qu,
  • Haimeng Yan,
  • Yifan Hou,
  • Wen Cao,
  • Yang Liu,
  • Enfan Zhang,
  • Jingsong He,
  • Zhen Cai

DOI
https://doi.org/10.1186/s13045-022-01224-4
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 24

Abstract

Read online

Abstract RNA demethylase ALKBH5 takes part in the modulation of N6-methyladenosine (m6A) modification and controls various cell processes. ALKBH5-mediated m6A demethylation regulates gene expression by affecting multiple events in RNA metabolism, e.g., pre-mRNA processing, mRNA decay and translation. Mounting evidence shows that ALKBH5 plays critical roles in a variety of human malignancies, mostly via post-transcriptional regulation of oncogenes or tumor suppressors in an m6A-dependent manner. Meanwhile, increasing non-coding RNAs are recognized as functional targets of ALKBH5 in cancers. Here we reviewed up-to-date findings about the pathological roles of ALKBH5 in cancer, the molecular mechanisms by which it exerts its functions, as well as the underlying mechanism of its dysregulation. We also discussed the therapeutic implications of targeting ALKBH5 in cancer and potential ALKBH5-targeting strategies.

Keywords